Clinical studies report significant reductions in RA symptoms and inflammatory biomarkers, such as C-reactive protein (CRP), with nVNS, alongside decreases in joint pain and swelling and improvements in patient-reported quality of life, which underscores its capacity to enhance daily functioning (Marsal et al., 2020a, 2021; Mondal et al., 2021). This evidence concerns the gene CRP and rheumatoid arthritis.